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We conducted a search for rare, functional variants altering 
susceptibility to Alzheimer’s disease that exploited knowledge 
of common variants associated with the same disease.  
We found that loss-of-function variants in ABCA7 confer risk  
of Alzheimer’s disease in Icelanders (odds ratio (OR) = 2.2,  
P = 2.2 × 0−3) and discovered that the association  
replicated in study groups from Europe and the United States 
(combined OR = 2.03, P = 6.8 × 0−5).
Alzheimer’s disease is a common neurodegenerative disorder with 
high heritability. The ε4 allele of APOE was found to associate with 
Alzheimer’s disease about 20 years ago1,2, and rare variants in three 
genes (APP, PSEN1 and PSEN2) were implicated in familial, early-
onset forms of the disease around the same time3. More recently, rare 
variants in APP and TREM2 were discovered to affect susceptibility 
to the sporadic, late-onset form of Alzheimer’s disease4–6, and the 
latest meta-analysis of common variants demonstrated that 19 loci, in 
addition to the APOE locus, harbor variants showing genome-wide 
significant association with Alzheimer’s disease7. The new common 
variant association regions include the major histocompatibility com-
plex (MHC) locus and 18 other regions in which the association signal 
extends over 104 genes (summarized in Supplementary Table 1)7.
We used our imputation of the whole-genome sequences of 2,636 
Icelanders into 104,220 long-range phased individuals and their 
close relatives8 to investigate whether any of the genes located in 
the regions showing common variant association with Alzheimer’s 
disease (excluding the MHC) also harbored rare variants confer-
ring higher risk. We considered two classes of variants: nonsense, 
frameshift or canonical splice-site variants (‘loss of function’), and 
missense or splice-site variants (‘missense’). Because loss-of-function 
mutations are likely to have the same biological effect—no protein is 
produced as a result of nonsense-mediated decay of mRNA contain-
ing premature stop codons—we collapsed these variants into a single 
allele and estimated one effect. Missense variants may have differ-
ent biological consequences; thus, for these variants, we ran analyses 
using SKAT9, a gene test that allows different effects, in addition to 
a collapsing test.
We carried out association testing using information from 3,419 
individuals with Alzheimer’s disease and 151,805 population con-
trols. For loss-of-function variants, collapsing tests using variants with 
minor allele frequency (MAF) <0.5% and information >0.8 resulted 
in examination of 20 genes in 10 common variant association regions. 
The most significant association result was for ABCA7 (OR = 2.08, 
P = 3.8 × 10−5) (Supplementary Table 2). For missense variants, 
we carried out collapsing tests for variants with MAF <0.5% and infor-
mation >0.8 (79 genes in 17 regions), and SKAT scans using both all 
variants with MAF <1% and information >0.8 (82 genes in 17 regions) 
and the subset of those variants predicted to be damaging or possibly 
damaging by PolyPhen (63 genes in 17 regions). The most significant 
result for the missense variant tests was for ABCA7, obtained using 
SKAT with all variants (P = 0.00020; Supplementary Tables 3 and 4).
As the most significant result for both the loss-of-function and 
missense variant scans was for ABCA7, we searched for functional 
commonality among the variants producing significance in the two 
scans. We found that the ABCA7 missense variant test was significant 
due to a single splice-site variant, c.5570+5G>C (P = 0.46 without 
this variant). Examination of transcripts from several c.5570+5G>C 
carriers using RNA sequencing (RNA-seq) showed that this vari-
ant led to mRNA containing intronic sequences (Supplementary 
Fig. 1) that eventually included a stop codon. Thus, c.5570+5G>C 
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could be included in the loss-of-function test, which then had an 
OR of 1.97 and a P value of 5.3 × 10−10.
We followed up the ABCA7 loss-of-function association result fur-
ther by carrying out Sanger sequencing of predicted variant carriers to 
validate the variants and to create a larger reference set for reimputa-
tion. Five of the six variants included in the original loss-of-function 
test as well as c.5570+5G>C and two variants not included in the ini-
tial scan because of low information scores were validated. All pairs of 
variants were uncorrelated (r2 < 0.001). Each of the variants was pre-
dicted to cause the insertion of a stop codon into the transcript before 
the last two exons. After reimputation, ABCA7 loss-of-function vari-
ants were associated with Alzheimer’s disease with an OR of 2.12 and a 
P value of 2.2 × 10−13 (Table 1).
Using our long-range phased haplotypes, we found that the ABCA7 
loss-of-function variants were never located on the background of 
rs4147929[A], the common variant previously associated with 
Alzheimer’s disease7. Thus, the loss-of-function variant association 
described here could not account for the common variant association, 
nor vice versa. We did not find evidence of interaction between the 
rare ABCA7 loss-of-function alleles and rs4147929[A] (P = 0.35).
To investigate the effect of these variants on Alzheimer’s disease 
outside Iceland, we genotyped the ABCA7 loss-of-function variants 
in study groups from Finland, Germany, Norway and the United 
States. We found six of the eight variants in at least one of the study 
groups (Supplementary Table 5). In the combined replication study 
groups, loss-of-function variants were associated with Alzheimer’s 
disease with an OR of 1.73 and a P value of 0.0056 (Table 2 and 
Supplementary Table 5). Meta-analysis with the Icelandic data 
yielded an OR of 2.03 and a P value of 6.8 × 10−15.
ABCA7, or ATP-binding cassette transporter A7, is a member 
of the A subfamily of ABC transporters that move primarily lip-
ids across membranes10. It is strongly expressed in brain, with the 
highest levels found in microglia10. ABCA7 promotes the efflux 
of phospholipids and cholesterol to apolipoprotein A-I (apoA-I) 
and apolipoprotein E (apoE) in cell culture11,12. ABCA7 is also an 
ortholog of the Caenorhabditis elegans gene 
ced-7, the product of which has a crucial role 
in the engulfment of apoptotic cells. In line 
with this function, ABCA7 is involved in the 
promotion of phagocytosis in several human 
cell lines13,14.
Recent results from mouse models sug-
gest that the primary function of ABCA7 is 
in the regulation of phagocytosis rather than 
in cholesterol metabolism. Abca7-null mice 
have only modestly altered serum cholesterol 
levels, and cholesterol and phospholipid 
efflux in macrophages isolated from these 
mice does not differ from that of wild-type 
macrophages15. In addition, although J20 
Abca7-null mice have greater insoluble amyloid β (Aβ) levels than 
J20 mice, they do not have elevated apoE concentrations, suggest-
ing that the increase in Aβ levels is not a result of increased efflux 
to apoE16.
To investigate whether genetic data provide any insights into the 
pathway through which ABCA7 acts, we tested for statistical inter-
action of the ABCA7 loss-of-function variants with either APOE 
ε4 or the Alzheimer’s disease–associated variant in TREM2, which 
encodes a protein involved in microglial activation17,18. We found no 
evidence of interaction of the ABCA7 loss-of-function variants with 
the Alzheimer’s disease–associated alleles of either APOE or TREM2 
(P = 0.72 and 0.38, respectively).
This study reinforces the claim that ABCA7, rather than neigh-
boring genes, is involved in the pathogenesis of Alzheimer’s disease. 
In addition, although it is currently unknown how the causal variant 
tagged by rs4147929[A] affects ABCA7 expression in the brain—both 
increased and decreased mRNA levels have been reported19,20—our 
results for the loss-of-function variants suggest that rs4147929[A] is 
likely to lead to reduced levels of the protein. Moreover, because of the 
high OR associated with ABCA7 loss-of-function variants, carriers of 
these variants should be useful participants in clinical studies seeking 
to improve the understanding and treatment of Alzheimer’s disease.
MEthOdS
Methods and any associated references are available in the online 
version of the paper.
Note: Any Supplementary Information and Source Data files are available in the 
online version of the paper.
AcKnOWLeDGMenTS
This work was done in collaboration with Illumina. The authors are grateful to the 
participants and their relatives. We also thank the staff and researchers at the Krókháls 
recruitment center, the Memory Clinic at the National Hospital of Iceland and the 
deCODE Genetics core facilities. This work was carried out with support from the 
Academy of Finland; EVO grant 5772708 of Kuopio University Hospital; the Strategic 
Funding of the University on Eastern Finland (University of Eastern Finland–Brain); 
the Sigrid Juselius Foundation; Framework Programme 7, grant agreement 601055; 
VPH Dementia Research Enabled by IT VPH-DARE@IT; the Research Council 
of Norway (223273, 225989, 237250/EU JPND); the K.G. Jebsen Foundation; the 
Norwegian Health Association; the AXA Research Fund, the Fondation Université 
Pierre et Marie Curie and the Fondation pour la Recherche sur Alzheimer, Paris, 
France; and the program ‘Investissements d’Avenir’ ANR-10-IAIHU-06.
AUTHOR cOnTRIBUTIOnS
S.S., H. Stefansson, T.J. and K.S. designed the study. S.S., H.J., A.I., H. Helgason, 
P.S., S.A.G., A.K. and U.U. carried out data analysis. O.T.M. performed 
experiments. S.H., H. Soininen, M.H., DemGene, D.A., T.F., I.D.U., S.D., S.B.S., 
L.R.W., G.-P.K., L.T.W., G.S., O.A.A., J.J.L., A.I.L., I.G., H. Hampel, D.R., P.V.J.,  
S.B. and J.S. diagnosed and recruited patients. S.S., H. Stefansson, T.J. and K.S. 
wrote the manuscript with the support of the remaining authors. 
table	1	 association	of	loss-of-function	variants	in	ABCA7	with	alzheimer’s	disease	in	iceland
Variant Positiona Rs ID MAF (%) OR P Info
p.Tyr622* Chr19:998,176 – 0.041 4.42 0.0034 0.98
p.Glu709Alafs*86 Chr19:998,507 – 0.274 2.14 0.0014 0.98
p.Arg1118* Chr19:100,4459 – 0.085 0.96 0.95 0.99
p.Leu1403Argfs*7 Chr19:1,006,907 – 0.085 1.78 0.25 0.99
c.4416+2T>G Chr19:1,007,244 rs113809142 0.129 4.47 3.4 × 10−7 0.99
p.Arg1561* Chr19:1,008,000 – 0.045 1.30 0.69 0.99
c.5570+5G>C Chr19:1,012,892 rs200538373 0.800 1.91 3.8 × 10−6 0.99
c.6044+1G>A Chr19:1,015,253 – 0.028 1.76 0.53 0.99
All – – 1.487 2.12 2.2 × 10−13 0.99
Variant names are based on RefSeq records NM_019112.3 and NP_061985.2. MAF, minor allele frequency in 
controls; OR, odds ratio.
aNCBI Build 36.
table	2	 association	of	loss-of-function	variants	in	ABCA7	with	
alzheimer’s	disease	in	four	non-icelandic	data	sets
Study n cases n controls MAF (%) OR P
United Sates (Emory) 409 406 0.49 2.50 0.18
Finland 515 588 0.60 2.13 0.12
Germany 522 1,917 0.94 1.33 0.38
Norway 919 1,405 0.50 1.86 0.097
All 2,365 4,316 – 1.73 0.0056
MAF, minor allele frequency in controls; OR, odds ratio.
©
20
15
N
at
ur
e 
A
m
er
ic
a,
 
In
c.
 
 
A
ll 
rig
ht
s 
re
se
rv
ed
.
Nature GeNetics  ADVANCE ONLINE PUBLICATION 3
br ief 	commun icat ions	
cOMPeTInG FInAncIAL InTeReSTS
The authors declare competing financial interests: details are available in the online 
version of the paper.
Reprints and permissions information is available online at http://www.nature.com/
reprints/index.html.
1. Saunders, A.M. et al. Neurology 43, 1467–1472 (1993).
2. Strittmatter, W.J. et al. Proc. Natl. Acad. Sci. USA 90, 1977–1981 (1993).
3. Cruts, M., Theuns, J. & Van Broeckhoven, C. Hum. Mutat. 33, 1340–1344 (2012).
4. Guerreiro, R. et al. N. Engl. J. Med. 368, 117–127 (2013).
5. Jonsson, T. et al. Nature 488, 96–99 (2012).
6. Jonsson, T. et al. N. Engl. J. Med. 368, 107–116 (2013).
7. Lambert, J.C. et al. Nat. Genet. 45, 1452–1458 (2013).
8. Kong, A. et al. Nat. Genet. 40, 1068–1075 (2008).
9. Wu, M.C. et al. Am. J. Hum. Genet. 89, 82–93 (2011).
10. Kim, W.S., Weickert, C.S. & Garner, B. J. Neurochem. 104, 1145–1166 (2008).
11. Abe-Dohmae, S. et al. J. Biol. Chem. 279, 604–611 (2004).
12. Wang, N. et al. J. Biol. Chem. 278, 42906–42912 (2003).
13. Iwamoto, N., Abe-Dohmae, S., Sato, R. & Yokoyama, S. J. Lipid Res. 47, 
1915–1927 (2006).
14. Jehle, A.W. et al. J. Cell Biol. 174, 547–556 (2006).
15. Kim, W.S. et al. J. Biol. Chem. 280, 3989–3995 (2005).
16. Kim, W.S. et al. J. Neurosci. 33, 4387–4394 (2013).
17. Griciuc, A. et al. Neuron 78, 631–643 (2013).
18. Takahashi, K., Rochford, C.D. & Neumann, H. J. Exp. Med. 201, 647–657 
(2005).
19. Allen, M. et al. Neurology 79, 221–228 (2012).
20. Vasquez, J.B., Fardo, D.W. & Estus, S. Neurosci. Lett. 556, 58–62 (2013).
norwegian Dementia Genetics consortium (DemGene):
Ina Selseth Almdahl9, Fred Andersen27, nenad Bogdanovic28, Anne Brækhus28, Knut engedal19, Arvid Rongve29,30, Ingvild Saltvedt14, 
eystein Stordal14,31 & Aree Witoelar11,17
27Department of Community Medicine, University of Tromsø, Tromsø, Norway. 28Geriatric Department, University Hospital Oslo and University of Oslo, Oslo, Norway. 
29Division of Mental Health, Helse Fonna, Haugesund, Norway. 30Department of Clinical Medicine, University of Bergen, Bergen, Norway. 31Department of Psychiatry, 
Namsos Hospital, Namsos, Norway.
©
20
15
N
at
ur
e 
A
m
er
ic
a,
 
In
c.
 
 
A
ll 
rig
ht
s 
re
se
rv
ed
.
br ief 	commun icat ions
Nature GeNetics doi:10.1038/ng.3246
ONLINE MEthOdS
Subjects. The subjects from Iceland, the United States (Emory University) 
and Germany have previously been described6. Briefly, patients from Iceland 
were diagnosed with definite, probable or possible Alzheimer’s disease on the 
basis of the NINCDS-ADRDA criteria21 (n = 1,035) or according to guidelines 
for ICD-10 F00 (n = 2,384) and were compared to population controls. The 
patients from Emory and Germany were diagnosed with probable Alzheimer’s 
disease according to the NINCDS-ADRDA criteria21 and were compared to 
either screened (Emory) or population (Germany) controls. The Norwegian 
sample included cases from 5 studies: the AHUS study (n = 75), the Dementia 
Study of Western Norway (DemVest; n = 82), the Dementia Study in Rural 
Northern Norway (n = 74), the Norwegian Memory Register study (n = 243) 
and the TrønderBrain study (n = 445). These cases were diagnosed accord-
ing to the ICD-10 research criteria22 (the Memory Register study and the 
Dementia Study in Rural Northern Norway), the recommendations from the 
National Institute on Aging–Alzheimer’s Association (NIA/AA)23 (AHUS) 
or the NINCDS-ADRDA criteria21 (DemVest and TrønderBrain). The con-
trols from Norway included screened controls obtained through the AHUS 
study (n = 89), the Dementia Study in Rural Northern Norway (n = 136) 
and the TrønderBrain study (n = 651) as well as population controls from 
the Norwegian Mother and Child Cohort Study (MoBa) conducted by the 
Norwegian Institute of Public Health24 (n = 381) and a lifespan study (n = 148). 
See the Supplementary Note for further information on the Norwegian 
studies. The Finnish sample consisted of 515 cases diagnosed with 
probable Alzheimer’s disease according to NINCDS-ADRDA clinical 
criteria21 and 588 age-matched controls; this sample has been described pre-
viously25. The Icelandic study was approved by the Data Protection Authority 
and the National Bioethics Committee, and the non-Icelandic studies were 
approved by local ethics boards. Participants giving samples also gave written, 
informed consent.
Genotyping and sequencing. Genotyping on Illumina arrays, whole-genome 
sequencing and variant calling of the Icelandic samples was carried out as 
previously described26. Validation of the sequencing and imputation results 
was performed using Sanger sequencing as detailed earlier26. Sample prepa-
ration, sequencing and analysis for RNA-seq were carried out as described 
in the Supplementary Note. Genotyping of the Emory, Finland, Germany 
and Norway samples was performed using Centaurus assays (p.Tyr622*, 
p.Leu1403Argfs*7, c.4416+2T>G, c.5570+5G>C and c.6044+1G>A) or Sanger 
sequencing (p.Glu709Alafs*86, p.Arg1118* and p.Arg1561*).
Long-range phasing, imputation and association testing. Long-range phas-
ing and imputation of the Icelandic sample were carried out as previously 
described26. The Alzheimer’s disease common variant association regions 
were defined as regions in which SNPs correlated (r2 > 0.2) with the most 
significant SNP at the locus showing association above baseline (Fig. 2 and 
Supplementary Figs. 2–11 in ref. 7). For the collapsing tests, appropriate 
variants in each gene were combined into a single allele, and analysis was 
conducted using logistic regression assuming a log-additive model for the 
two alleles and including sex, age, age2 and county of birth as covariates. The 
SKAT9 scan included the same covariates as the collapsing tests. Annotation 
was performed using VEP27 on the basis of RefSeq transcripts. Variants were 
defined as ‘probably damaging’ or ‘possibly damaging’ using the PolyPhen-2 
HDIV database28. For the collapsing and individual-variant tests, we included 
information both from typed individuals (2,476 cases and 65,347 controls) 
and untyped, related individuals (943 cases and 86,458 controls) as previously 
described26. For the SKAT scans, only information from typed individuals 
was used. Genomic control29 was applied to all Icelandic tests to account for 
relatedness. Association testing in the replication study groups was carried out 
using Fisher’s exact test, and the results from the different replication study 
groups were combined using the exact Mantel-Haenzel test.
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